伤口护理生物製剂市场机会、成长动力、产业趋势分析及 2025-2034 年预测

2024 年全球伤口护理生物製剂市场价值为 22 亿美元，预计 2025 年至 2034 年期间的复合年增长率为 5.2%。伤口护理生物製剂是一种生物工程治疗方法，旨在增强人体的自然癒合反应，特别是针对慢性和无法癒合的伤口。这些解决方案透过加速组织修復，有助于最大限度地降低包括截肢在内的严重併发症的风险。慢性伤口盛行率的上升、手术数量的增加以及人口老化正在推动市场成长。烧伤和慢性伤口常见的地区对生物製剂的需求尤其高。医疗设施不足、感染风险较高等因素导致伤口癒合时间延长，进一步增加了对生物治疗的依赖。此外，随着老年人口的增长，压疮和糖尿病足溃疡等疾病的发生率较高，对有效伤口癒合解决方案的需求也不断增加。生物疗法的进步也促进了市场的扩张，从而提高了治疗效果。

根据产品类型，市场分为皮肤替代品和外用药物。 2023 年整体市场价值为 21 亿美元，其中皮肤替代品市场领先，2024 年将达到 14 亿美元。这些产品提供结构支撑并促进慢性和急性伤口的组织再生。源自人类、动物或合成来源的皮肤替代品可缩短伤口闭合时间并最大限度地降低感染风险，使其成为治疗的首选。慢性伤口的日益普及是推动该领域需求的关键因素，因为这些生物製剂显着提高了癒合效率。

根据伤口类型，市场分为糖尿病足溃疡、静脉性腿部溃疡、压疮、手术伤口、烧伤和其他伤口。手术伤口部分占 2024 年市场总收入的 27%，预计到 2034 年将达到 8.775 亿美元。预防手术部位感染、加速术后恢復和增强组织再生的需求日益增长，推动了对生物伤口护理产品的需求。全球手术数量的增加进一步加强了该领域的市场地位，因为生物製剂在减少併发症和改善患者预后方面发挥着至关重要的作用。

最终使用者部分包括医院、门诊手术中心和其他医疗机构。 2024 年，医院占据市场主导地位，收入份额为 43.8%，这得益于生物伤口护理解决方案被广泛采用，用于治疗复杂伤口，包括糖尿病足溃疡、烧伤、压疮和术后伤口。先进皮肤替代品、生长因子疗法和胶原蛋白敷料的使用日益增多，提高了癒合效果，同时降低了感染率。医院内再生治疗服务的扩展进一步支持了市场的成长。

美国伤口护理生物製剂市场取得了显着增长，收入从 2023 年的 7.308 亿美元增长到预计 2034 年的 12 亿美元。慢性伤口负担的增加和糖尿病患者的增加导致了这一上升趋势。对先进伤口护理解决方案的需求不断增加，加强了生物製剂在现代伤口管理中的作用。

目录

第一章：方法论与范围

第二章：执行摘要

第三章：行业洞察

• 产业生态系统分析
• 产业衝击力
  • 成长动力
    • 发展中和欠发达地区烧伤人数不断增加
    • 全球老年人口不断增加
    • 伤口护理生物製剂的技术进步
    • 政府关于伤口护理治疗的措施激增
  • 产业陷阱与挑战
    • 欠发达经济体缺乏训练有素的医生
• 成长潜力分析
• 监管格局
• 技术格局
• 未来市场趋势
• 差距分析
• 波特的分析
• PESTEL分析

第四章：竞争格局

• 介绍
• 公司市占率分析
• 公司矩阵分析
• 主要市场参与者的竞争分析
• 竞争定位矩阵
• 策略仪表板

第五章：市场估计与预测：依产品类型，2021 年至 2034 年

• 主要趋势
• 皮肤替代品
  • 生物
    • 同种异体移植
    • 异种移植
    • 其他生物皮肤替代品
  • 合成的
• 外用药物

第六章：市场估计与预测：按伤口类型，2021 年至 2034 年

• 主要趋势
• 糖尿病足溃疡
• 静脉性腿部溃疡
• 压疮
• 手术伤口
• 烧伤
• 其他伤口类型

第七章：市场估计与预测：依最终用途，2021 年至 2034 年

• 主要趋势
• 医院
• 门诊手术中心
• 其他最终用途

第八章：市场估计与预测：按地区，2021 年至 2034 年

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 荷兰
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中东和非洲
  • 沙乌地阿拉伯
  • 南非
  • 阿联酋

第九章：公司简介

• 3M
• Amnio Technology
• Avita Medical
• Convatec
• Derma Sciences
• Integra Life Sciences
• Kerecis
• Mimedx Group
• Mölnlycke Health Care
• Organogenesis
• Osiris Therapeutics
• Skye Biologics
• Smith & Nephew
• Solsys Medical
• Vericel Corporation
• Wright Medical

The Global Wound Care Biologics Market was valued at USD 2.2 billion in 2024 and is projected to expand at a CAGR of 5.2% from 2025 to 2034. Wound care biologics are bioengineered treatments designed to enhance the body's natural healing response, particularly for chronic and non-healing wounds. These solutions help minimize the risk of severe complications, including amputation, by accelerating tissue repair. The rising prevalence of chronic wounds, the increasing number of surgeries, and the aging population are driving market growth. The demand for biologics is particularly high in regions where burn injuries and chronic wounds are prevalent. Factors such as inadequate medical facilities and higher infection risks contribute to prolonged wound healing, further increasing the reliance on biologic treatments. Additionally, as the geriatric population grows, the need for effective wound healing solutions continues to rise due to the higher incidence of conditions such as pressure ulcers and diabetic foot ulcers. The market's expansion is also supported by advancements in biologic therapies that offer enhanced healing outcomes.

The market is segmented based on product type into skin substitutes and topical agents. The overall market was valued at USD 2.1 billion in 2023, with the skin substitutes segment leading at USD 1.4 billion in 2024. These products offer structural support and promote tissue regeneration in both chronic and acute wounds. Skin substitutes, derived from human, animal, or synthetic sources, reduce wound closure time and minimize infection risks, making them the preferred choice in treatment. The growing prevalence of chronic wounds is a key factor driving demand in this segment, as these biologics significantly enhance healing efficiency.

Based on wound type, the market is categorized into diabetic foot ulcers, venous leg ulcers, pressure ulcers, surgical wounds, burns, and other wounds. The surgical wounds segment accounted for 27% of the total market revenue in 2024 and is projected to reach USD 877.5 million by 2034. The increasing need to prevent surgical site infections, accelerate post-surgical recovery, and enhance tissue regeneration is fueling the demand for biologic wound care products. The rising number of surgeries performed globally is further strengthening the market position of this segment, as biologics play a crucial role in reducing complications and improving patient outcomes.

The end-user segment consists of hospitals, ambulatory surgical centers, and other healthcare facilities. Hospitals dominated the market with a 43.8% revenue share in 2024, driven by the widespread adoption of biologic wound care solutions for managing complex wounds, including diabetic foot ulcers, burns, pressure ulcers, and post-surgical wounds. The increasing use of advanced skin substitutes, growth factor therapies, and collagen-based dressings is enhancing healing outcomes while lowering infection rates. The expansion of regenerative therapy services within hospitals further supports market growth.

The U.S. wound care biologics market has seen significant growth, with revenues rising from USD 730.8 million in 2023 to a projected USD 1.2 billion by 2034. The increasing burden of chronic wounds and a rising diabetic population contribute to this upward trend. The demand for advanced wound care solutions continues to escalate, reinforcing the role of biologics in modern wound management.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising burn injuries in developing and underdeveloped regions
    • 3.2.1.2 Increasing geriatric population globally
    • 3.2.1.3 Technological advancements in wound care biologics
    • 3.2.1.4 Surge in government initiatives regarding wound care treatment
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Lack of trained physicians in underdeveloped economies
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Technological landscape
• 3.6 Future market trends
• 3.7 Gap analysis
• 3.8 Porter's analysis
• 3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product Type, 2021 – 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Skin substitutes
  • 5.2.1 Biological
    • 5.2.1.1 Allograft
    • 5.2.1.2 Xenograft
    • 5.2.1.3 Other biological skin substitutes
  • 5.2.2 Synthetic
• 5.3 Topical agents

Chapter 6 Market Estimates and Forecast, By Wound Type, 2021 – 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Diabetic foot ulcers
• 6.3 Venous leg ulcers
• 6.4 Pressure ulcers
• 6.5 Surgical wounds
• 6.6 Burns
• 6.7 Other wound types

Chapter 7 Market Estimates and Forecast, By End Use, 2021 – 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Hospitals
• 7.3 Ambulatory surgical centers
• 7.4 Other end use

Chapter 8 Market Estimates and Forecast, By Region, 2021 – 2034 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 India
  • 8.4.3 Japan
  • 8.4.4 Australia
  • 8.4.5 South Korea
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
• 8.6 Middle East and Africa
  • 8.6.1 Saudi Arabia
  • 8.6.2 South Africa
  • 8.6.3 UAE

Chapter 9 Company Profiles

• 9.1 3M
• 9.2 Amnio Technology
• 9.3 Avita Medical
• 9.4 Convatec
• 9.5 Derma Sciences
• 9.6 Integra Life Sciences
• 9.7 Kerecis
• 9.8 Mimedx Group
• 9.9 Mölnlycke Health Care
• 9.10 Organogenesis
• 9.11 Osiris Therapeutics
• 9.12 Skye Biologics
• 9.13 Smith & Nephew
• 9.14 Solsys Medical
• 9.15 Vericel Corporation
• 9.16 Wright Medical